Join        Login             Stock Quote

InVivo's Jason Fowler Wins 2012 Ironman World Championship

Monday, December 24, 2012 6:00 AM

InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today congratulates InVivo Therapeutics’ sponsored athlete Jason Fowler on winning the 2012 Ironman 70.3 World Triathlon Championships in Las Vegas, NV.

Jason Fowler (Photo: Business Wire)

Jason Fowler (Photo: Business Wire)

As a nationally ranked amateur motocross racer, Fowler was paralyzed from the chest down at the age of 17 as the result of a motorcycle accident. Following his accident Fowler remained an avid athlete, and has since completed 150 road races, 30 marathons, and 29 triathlons, and has won several local and national competitions including two World Championships. He also regularly volunteers his time to traumatically injured children and trains aspiring athletes.

Most recently, Fowler took first place in the 2012 Ironman 70.3 World Triathlon Championships in Las Vegas, NV. As a triathlete, Fowler competes conventionally in the swim and participates in the bike ride stage using a handcycle, and in the run portion using a racing wheelchair. Remarkably, the entire distance of the race is covered using only the strength and endurance of the upper body.

“Jason’s commitment to his sport is only exceeded by his commitment to the spinal cord injury community,” said Frank Reynolds, InVivo Chief Executive Officer. “We all know the importance of first responders at any emergency, but well after the doctors, nurses, and rehabilitation experts finish their work, Jason and his team at the Boston Chapter of the National Spinal Cord Injury Association arrive to teach patients how to adjust and adapt to a new set of possibilities for their lives. Jason is a Ironnman in every sense of the word.”

To read more and see a great video about Jason, please visit: www.jasonfowlerracing.com/ and http://boston.cbslocal.com/2012/12/05/paraplegic-athlete-from-belmont-crowned-iron-man-champion-of-world/.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Certain statements contained in this press release that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, and the Company intends that such statements are subject to the safe harbor created thereby. These statements include, but are not limited to, those relating to the expected approval of the FDA to conduct human clinical trials for the Company’s products, the expected commencement date of any approved human clinical trials, the expected size of the pilot study, the expectation that the scaffold product will be regulated under a HDE pathway, and the expected acceleration of commercialization of the Company’s products resulting therefrom. These forward-looking statements are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to obtain FDA approval to conduct human clinical trials; whether the human clinical trials produce acceptable results; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our Annual Report on Form 10-K for the year ended December 31, 2011 and subsequent filings with the SEC.

Forward-looking statements contained in this press release speak only as of the date of this release. Subsequent events or circumstances occurring after such date may render these statements incomplete or out of date. The Company undertakes no obligation and expressly disclaims any duty to update such statements.

(Source: Business Wire )
(Source: Quotemedia)


Related Stories

  • No Stories Found


Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.